N-{3,5-dichloro-4-[4-hydroxy-3-(indan-1-ylaminomethyl)-phenoxy]-phenyl}-oxamic acid methyl ester | 290351-47-2

• 分子结构分类: 有机化合物
• 英文名称: N-{3,5-dichloro-4-[4-hydroxy-3-(indan-1-ylaminomethyl)-phenoxy]-phenyl}-oxamic acid methyl ester
• 英文别名: methyl 2-[3,5-dichloro-4-[3-[(2,3-dihydro-1H-inden-1-ylamino)methyl]-4-hydroxyphenoxy]anilino]-2-oxoacetate
• CAS: 290351-47-2
• 化学式: C₂₅H₂₂Cl₂N₂O₅
• 分子量: 501.366
• InChiKey: QRRJGHDTHUUKMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  96.9
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Oxamic acids and derivatives as thyroid receptor ligands
  申请人：——

  公开号：US20030114521A1

  公开（公告）日：2003-06-19

  The present invention provides novel compounds of the Formula 1 and prodrugs thereof, geometric and optical isomers thereof, and pharmaceutically acceptable salts of such compounds, prodrugs and isomers, wherein R 1 —R 8 and W are as described herein. Pharmaceutical compositions containing such compounds, prodrugs, isomers or pharmaceutically acceptable salts thereof, and methods, pharmaceutical compositions and kits for treating obesity, hyperlipidemia, glaucoma, cardiac arrhythmia, skin disorders, thyroid disease, hypothyroidism and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis are also provided.

  本发明提供了式1的新化合物及其前药、几何和光学异构体以及这些化合物、前药和异构体的药学上可接受的盐，其中R1-R8和W如本文所述。还提供了含有这些化合物、前药、异构体或其药学上可接受的盐的药物组合物，以及用于治疗肥胖症、高脂血症、青光眼、心律失常、皮肤疾病、甲状腺疾病、甲状腺功能减退症以及相关的疾病和疾病，如糖尿病、动脉硬化、高血压、冠心病、高胆固醇血症、抑郁症和骨质疏松症的方法、药物组合物和工具包。
• OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS
  申请人：Pfizer Products Inc.

  公开号：EP1157001A1

  公开（公告）日：2001-11-28
• US6326398B1
  申请人：——

  公开号：US6326398B1

  公开（公告）日：2001-12-04
• US6545018B2
  申请人：——

  公开号：US6545018B2

  公开（公告）日：2003-04-08
• [EN] OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS<br/>[FR] ACIDES OXAMIQUES ET DERIVES UTILISES EN TANT QUE LIGANDS DU RECEPTEUR DES HORMONES THYROIDIENNES
  申请人：PFIZER PROD INC

  公开号：WO2000051971A1

  公开（公告）日：2000-09-08

  The present invention provides novel compounds of Formula (I) and prodrugs thereof, geometric and optical isomers thereof, and pharmaceutically acceptable salts of such compounds, prodrugs and isomers, wherein R1 - R8 and W are as described herein. Pharmaceutical compositions containing such compounds, prodrugs, isomers or pharmaceutically acceptable salts thereof, and methods, pharmaceutical compositions and kits for treating obesity, hyperlipidemia, glaucoma, cardiac arrythmia, skin disorders, thyroid disease, hypothyroidism and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis are also provided.